Goldman Sachs Asset Management, Asia Investment Capital and GGV Capital have led a $300 million funding round in MegaRobo Technologies, according to a report by Reuters.

Goldman Sachs Asset Management, Asia Investment Capital and GGV Capital have led a $300 million funding round in MegaRobo Technologies, according to a report by Reuters.

The six-year-old Chinese company employs AI and robotics in life sciences research and is the latest pharmaceutical industry start-up to benefit from increases investor interest in the sector following the Covid-19 pandemic.